Table 4.
L-Triiodothyronine Pharmacokinetics Studies
| Study | Study population | Methods | Half-life hours | Tmax hours | Notes |
|---|---|---|---|---|---|
| Nicoloff et al. (16) | 8 Healthy volunteers | 125I LT3 disappearance rate | 17 | n/a | Intravenous infusion |
| Cavalieri et al. (17) | 5 Healthy volunteers | 131I LT3 disappearance rate | 22 | n/a | Intravenous infusion |
| Woeber et al. (19) | 7 Healthy volunteers | 131I LT3 disappearance rate | 24 | n/a | Intravenous infusion |
| Saberi and Utiger (20) | 8 Hypothyroid | Single daily dose 25 and 50 mcg Immunoassay |
12* | 4–6 | *Estimated from graphic |
| Lieblich and Utiger (21) | 5 Healthy volunteers | Single dose 100 mcg Immunoassay |
16* | 3 | *Estimated from graphic |
| Surks et al. (22) | 4 Hypothyroid (thyroidectomy) | Single dose 75 mcg Immunoassay |
10* | 1.5 | *Estimated from graphic |
| Jonklaas et al. (38) | 12 Healthy volunteers | Single dose 50 mcg Immunoassay |
22 | 2.5 | Compound originally developed as extended release |
| This study | 14 Thyroidectomized patients-on LT3 | Single dose weight-based, terminal elimination | Distribution 2.3 Elimination 22.9 |
1.9 | 11-Day observation Two compartments |
| This study | 5 Thyroidectomized patients-hypothyroid | Single dose weight-based | 3.62 | 2.9 | 12-Hour observation |
131I, radioactive iodine; n/a, not applicable.